Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06813781 · ClinicalTrials.gov registry record · Phase 1
Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of AZD5004
A Phase 1 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 1
- Development phase
- 33
- Enrollment target
NCT06813781 is a Phase 1 study that has completed, run by AstraZeneca. The registered enrollment target is 33 participants.
The verdict
NCT06813781, a Phase 1 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 33 participants
- Enrollment target
Study Summary
This is a Phase I, multicentre, single-dose, non-randomised, open-label, parallel-group study to examine the PK, safety, and tolerability of AZD5004 in male and female participants with mild, moderate, and severe hepatic impairment compared with participants with normal hepatic function.
Interventions
- DRUG AZD5004
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2024-12-19 |
| Est. Completion | 2025-10-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06813781
The ClinicalTrials.gov registry entry for NCT06813781 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 33 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which AZD5004 is the first listed.
NCT06813781 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06813781 about?
NCT06813781 is a clinical study titled "Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of AZD5004". This is a Phase I, multicentre, single-dose, non-randomised, open-label, parallel-group study to examine the PK, safety, and tolerability of AZD5004 in male and female participants with mild, moderate, and severe hepatic impairment compared with participants with normal hepatic function.
What is the current status of trial NCT06813781?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 33 participants. The study started on 2024-12-19. Estimated completion is 2025-10-02.
What interventions are being tested in trial NCT06813781?
The interventions under investigation include: AZD5004 (DRUG).
Who is sponsoring clinical trial NCT06813781?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.